FHTX

Foghorn Therapeutics Inc.

5.21 USD
-0.02 (-0.38%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Foghorn Therapeutics Inc. stock is down -16.24% since 30 days ago. The next earnings date is Aug 2, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 75% of the previous 3 June’s closed higher than May.

About Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc. is developing a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome. The company is also developing an enzyme inhibitor and protein degrader as selective modulators of BRM.